thus, rather than replacing hormone levels to improve vascular function in estrogen-deficient postmenopausal women and in men with low testosterone, it may be more beneficial to target the mechanisms (potentially cellular senescence) by which the reductions in these hormones drive vascular aging
"CagriSema efficacy and safety in obesity treatment: Phase 3 REDEFINE trial results." The Lancet Diabetes & Endocrinology , 12(3), 201-213
This could cause a potential response bias, as more affected patients might be more prone to complete the forms
They're offered in several brand name forms, like Ozempic, where semaglutide is the main substance, or Zepbound, where tirzepatide is the main substance
The studies reported an absolute change of -1.8 cm in one trial and -1.3 cm in another